S
Silvio Danese
Researcher at Humanitas University
Publications - 1184
Citations - 47449
Silvio Danese is an academic researcher from Humanitas University. The author has contributed to research in topics: Ulcerative colitis & Medicine. The author has an hindex of 90, co-authored 893 publications receiving 35801 citations. Previous affiliations of Silvio Danese include The Catholic University of America & Catholic University of the Sacred Heart.
Papers
More filters
Journal ArticleDOI
Covid-19 digestive system involvement and clinical outcomes in a large academic hospital in Milan, Italy.
Alessio Aghemo,Daniele Piovani,Tommaso Lorenzo Parigi,Enrico Brunetta,Nicola Pugliese,Edoardo Vespa,Paolo Omodei,Paoletta Preatoni,Ana Lleo,Alessandro Repici,Antonio Voza,Maurizio Cecconi,A. Malesci,Stefanos Bonovas,Silvio Danese +14 more
TL;DR: Since February 2020, the COVID-19 pandemic has spread to Italy affecting more than 100,000 people and its timing, clinical significance, and possible impact on viral spread of GI symptoms presentation have not been fully elucidated.
Journal ArticleDOI
Risankizumab as induction therapy for Crohn's disease: results from the phase 3 ADVANCE and MOTIVATE induction trials
Geert R. D'Haens,Remo Panaccione,Filip Baert,Patrick M.M. Bossuyt,Jean-Frederic Colombel,Silvio Danese,Marla Dubinsky,Brian G. Feagan,Tadakazu Hisamatsu,Allen Lim,James O. Lindsay,Edward V. Loftus,Julián Panés,Laurent Peyrin-Biroulet,Zhihua Ran,David T. Rubin,William J. Sandborn,Stefan Schreiber,Ezequiel Neimark,An Song,Kristina Kligys,Yinuo Pang,Valerie L. Pivorunas,Sofie Berg,W. Rachel Duan,Bidan Huang,Jasmina Kalabic,Xiaomei Liao,Anne M. Robinson,Kori Wallace,Marc Ferrante +30 more
TL;DR: All coprimary endpoints at week 12 were met in both trials with both doses of risankizumab, and the intention-to-treat population (all eligible patients who received at least one dose of study drug in the 12-week induction period) was analysed for efficacy outcomes.
Journal ArticleDOI
Guselkumab for the treatment of Crohn's disease: Induction results from the Phase 2 GALAXI-1 study.
William J. Sandborn,Geert R. D'Haens,Walter Reinisch,Julián Panés,Daphne Chan,Susana Gonzalez,Kathleen M. Weisel,Matthew Germinaro,Mary Ellen Frustaci,Zijiang Yang,Omoniyi J. Adedokun,Chenglong Han,Remo Panaccione,Tadakazu Hisamatsu,Silvio Danese,David T. Rubin,Bruce E. Sands,Anita Afzali,Jane M. Andrews,Brian G. Feagan +19 more
TL;DR: Greater proportions of patients receiving guselkumab achieved clinical response, PRO-2 remission, clinical-biomarker response, and endoscopic response at week 12 vs placebo, and Efficacy of ustekinumab vs placebo was demonstrated.
Journal ArticleDOI
TREM-1 Inhibition Restores Impaired Autophagy Activity and Reduces Colitis in Mice.
Tunay Kökten,Sébastien Gibot,Patricia Lepage,Silvia D'Alessio,Julie Hablot,Ndeye-Coumba Ndiaye,Hélène Busby-Venner,Céline Monot,Benjamin Garnier,David Moulin,Jean-Yves Jouzeau,Franck Hansmannel,Silvio Danese,Jean-Louis Guéant,Sylviane Muller,Laurent Peyrin-Biroulet +15 more
TL;DR: It is confirmed that inhibition of TREM-1 attenuates the severity of colitis clinically, endoscopically and histologically, and may represent a novel drug target for the treatment of IBD, by modulating autophagy activity and ER stress.
Journal ArticleDOI
Full Interchangeability in Regard to Immunogenicity Between the Infliximab Reference Biologic and Biosimilars CT-P13 and SB2 in Inflammatory Bowel Disease.
Gionata Fiorino,M. Begoña Ruiz-Argüello,A Maguregui,Daniel Nagore,Carmen Correale,Simona Radice,Daniela Gilardi,Mariangela Allocca,F Furfaro,Antonio Martínez,Silvio Danese +10 more
TL;DR: Data support full interchangeability between biosimilars in regard to immunogenicity and suggest that immunodominant epitopes in the reference and CT-P13 drugs are equally present in SB2.